MASSHealthcare · Medical DevicesThe 6 Wall Street analysts covering 908 Devices, Inc. hold a median 12-month price target of $14 — +22.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 80 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores 908 Devices, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (87): Sales and profits are climbing, and climbing faster than before.
Volatility (41): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on MASS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +22.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | Canaccord Genuity | Initiates | Buy | $14 |
| 12 Aug 2026 | Roth Capital | Maintains | Buy | — |
| 12 Aug 2026 | Roth Capital | Maintains | Buy | $11 → $13 |
| 12 Aug 2026 | Stifel | Maintains | Buy | — |
| 12 Aug 2026 | Stifel | Maintains | Buy | $10 → $12 |
| 29 July 2026 | Roth Capital | Initiates | Buy | $11 |
| 29 July 2026 | Roth Capital | Initiates | Buy | — |
| 5 Aug 2025 | Leerink Partners | Upgrade | Outperform | $12 |
| 5 Aug 2025 | Leerink Partners | Upgrade | Outperform | — |
| 15 Jan 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 13 Nov 2024 | Leerink Partners | Downgrade | Market Perform | — |
| 13 Nov 2024 | Stifel | Maintains | Buy | — |
| 17 Oct 2024 | Leerink Partners | Maintains | Outperform | — |
| 13 May 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 25 Sept 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 7 Feb 2023 | Stephens & Co. | Initiates | Overweight | — |
| 6 Jan 2023 | SVB Leerink | Maintains | Outperform | — |
| 15 Nov 2022 | SVB Leerink | Maintains | Outperform | — |
| 8 Mar 2022 | SVB Leerink | Maintains | Outperform | — |
| 14 May 2021 | SVB Leerink | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MASS appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, 908 Devices, Inc. returned +47.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 36% of US stocks
Cheaper than 16% of US stocks
Cheaper than 27% of US stocks
Cheaper than 91% of US stocks
Higher than 73% of US stocks
Higher than 62% of US stocks
Higher than 64% of US stocks
Higher than 18% of US stocks
Higher than 9% of US stocks
Higher than 30% of US stocks
Higher than 30% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
908 Devices, Inc. has a market value of $465.0M and an enterprise value of $367.8M.
Revenue in the twelve months to 30 June 2026: $60.8M. The latest quarter grew 23.3% year on year.
Net income over the same four quarters: −$34.7M, a −57.0% net margin.
Diluted earnings per share, trailing twelve months: $−0.95.
Free cash flow in the twelve months to 30 June 2026: $615K.
Trailing P/E: 20.8×; forward P/E: −36.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
908 Devices, Inc. employs 172 people — $354K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own 908 Devices, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Riverwater Micro Opportunities Strategy reported initiating a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military.
Why it matters — The report indicates that the strategy added MASS to its portfolio.
908 Devices said it will report third-quarter 2026 financial results before the market opens on November 10, 2026. Management will host a related webcast conference call at 8:30 a.m. Eastern Time.
Why it matters — MASS watchers can note the scheduled date and time for the company’s upcoming results and management call.
908 Devices announced that its management will present at the 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City, with the presentation scheduled for 3:45 p.m. Eastern Time and webcast for interested registrants.
Why it matters — The company's participation offers MASS watchers an opportunity to hear management discuss its handheld chemical analysis tools within the context of aerospace and defense applications.
908 Devices reported second-quarter 2026 results featuring revenue growth, a narrower adjusted EBITDA loss, and increasing recurring revenue. The company also outlined its strategy to expand in handheld chemical detection and raised its 2026 outlook.
Why it matters — A raised outlook and improving financial metrics signal accelerating demand for the company's handheld detection products, a key area of its growth strategy.
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago, as presented at the TG Therapeutics conference.
Why it matters — MASS watchers would care because the company is positioning itself around a concentrated handheld detection portfolio for public safety and defense after its life-sciences divestiture.
The 6 Wall Street analysts covering 908 Devices, Inc. have a median 12-month price target of $14, with estimates ranging from $12 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering 908 Devices, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 908 Devices, Inc. 80 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, 908 Devices, Inc. ranks 80 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (87 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +22.2% from the last close, and Ticker Nerd's factor model ranks 908 Devices, Inc. 80 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering 908 Devices, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MASS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $14 over the next 12 months.
908 Devices, Inc. returned +47.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
908 Devices Inc. is a medical technology company that develops handheld and desktop chemical analysis instruments for point-of-need testing.
The most recent item we track (Seeking Alpha, 30 Oct 2026): "Riverwater Micro Opportunities Strategy Q3 2026 Portfolio Activity". Riverwater Micro Opportunities Strategy reported initiating a position in 908 Devices, a maker of portable chemical detection instruments used by hazmat teams, law enforcement, firefighters, and the military.
908 Devices Inc. is a medical technology company that develops handheld and desktop chemical analysis instruments for point-of-need testing. Its product portfolio centers on portable mass spectrometry and spectroscopy systems used to detect, identify, and monitor unknown substances in demanding environments. The company’s devices support applications across health, safety, and defense, including field screening for hazardous chemicals, drugs, explosives, gases, and other materials that require rapid analysis outside traditional laboratories. 908 Devices also serves markets such as life sciences research, bioprocessing, biopharma, forensics, and industrial analysis with tools designed for faster, more accessible sample interrogation. Headquartered in Burlington, Massachusetts, 908 Devices focuses on making advanced analytical capabilities available in compact formats that can be used directly at the point of need.
CEO Dr. Kevin J. Knopp Ph.D. · 172 employees · United States · https://908devices.com
